SCI-210
Autism Spectrum Disorder (ASD)
Phase IIActive
Key Facts
About SciSparc
SciSparc is a clinical-stage biotech focused on developing optimized cannabinoid-based combination therapies for CNS disorders. Its mission is to create safer, more effective pharmaceutical treatments by synergistically combining cannabinoids with approved drugs. Key achievements include advancing its lead candidate for Tourette syndrome into a Phase IIb trial and securing intellectual property for its platform. The strategy is to de-risk development by repurposing known molecules while building a pipeline anchored in proprietary synergistic combinations.
View full company profileTherapeutic Areas
Other Autism Spectrum Disorder (ASD) Drugs
| Drug | Company | Phase |
|---|---|---|
| PAX-101 (IV Suramin) | PaxMedica | Phase 3 |
| eTNS Platform | NeuroSigma | Unknown |
| CM-AT | Curemark | Phase 3 |
| DT402 | Definium Therapeutics | Phase 2a |
| ML-004 | MapLight Therapeutics | Phase 1 |